- Home
- KBR vs AXSM Comparison
KBR vs AXSM Comparison
Compare KBR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- AXSM
- Stock Information
- Founded
- KBR 1901
- AXSM 2012
- Country
- KBR United States
- AXSM United States
- Employees
- KBR N/A
- AXSM N/A
- Industry
- KBR Military/Government/Technical
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- AXSM Health Care
- Exchange
- KBR Nasdaq
- AXSM Nasdaq
- Market Cap
- KBR 6.3B
- AXSM 5.1B
- IPO Year
- KBR 2006
- AXSM 2015
- Fundamental
- Price
- KBR $51.98
- AXSM $110.11
- Analyst Decision
- KBR Strong Buy
- AXSM Strong Buy
- Analyst Count
- KBR 7
- AXSM 16
- Target Price
- KBR $67.57
- AXSM $171.13
- AVG Volume (30 Days)
- KBR 1.5M
- AXSM 591.2K
- Earning Date
- KBR 07-23-2025
- AXSM 05-05-2025
- Dividend Yield
- KBR 1.27%
- AXSM N/A
- EPS Growth
- KBR N/A
- AXSM N/A
- EPS
- KBR 2.98
- AXSM N/A
- Revenue
- KBR $7,979,000,000.00
- AXSM $432,157,000.00
- Revenue This Year
- KBR $14.27
- AXSM $63.16
- Revenue Next Year
- KBR $8.57
- AXSM $60.81
- P/E Ratio
- KBR $17.46
- AXSM N/A
- Revenue Growth
- KBR 12.84
- AXSM 72.16
- 52 Week Low
- KBR $43.89
- AXSM $64.11
- 52 Week High
- KBR $72.60
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- KBR 46.38
- AXSM 56.24
- Support Level
- KBR $50.53
- AXSM $101.41
- Resistance Level
- KBR $52.27
- AXSM $106.77
- Average True Range (ATR)
- KBR 1.23
- AXSM 2.88
- MACD
- KBR -0.42
- AXSM 0.34
- Stochastic Oscillator
- KBR 27.54
- AXSM 87.01
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.